Human stem cell osteoblastogenesis mediated by novel glycogen synthase kinase 3 inhibitors induces bone formation and a unique bone turnover biomarker profile in rats

Toxicology and Applied Pharmacology

Volumn 272, Issue 2, 2013, Pages 399-407

  Gilmour, Peter S ^a   O'Shea, Patrick J ^a   Fagura, Malbinder ^a   Pilling, James E ^b   Sanganee, Hitesh ^a   Wada, Hiroki ^a   Courtney, Paul F ^a   Kavanagh, Stefan ^a   Hall, Peter A ^a   Escott, K Jane ^a  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

catenin; Biomarkers; Bone turnover; In vivo; Stromal stem cells; Wnt

Indexed keywords

AR 79; AZ 13282107; AZD 2858; BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; UNCLASSIFIED DRUG;

ADIPOSE DERIVED STEM CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOSYNTHESIS; BLOOD SAMPLING; BONE DENSITY; BONE DEVELOPMENT; BONE MASS; BONE MINERALIZATION; BONE TURNOVER; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; FEMUR; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; MESENCHYMAL STEM CELL; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOBLASTOGENESIS; OSTEOLYSIS; PROTEIN PHOSPHORYLATION; RAT; STEM CELL; STRUCTURE ANALYSIS; THICKNESS; TRABECULAR BONE;

Β-CATENIN; BIOMARKERS; BONE TURNOVER; IN VIVO; STROMAL/STEM CELLS; WNT;

ANIMALS; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; CELL DIFFERENTIATION; ENZYME INHIBITORS; FEMALE; FEMUR; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MESENCHYMAL STROMAL CELLS; MOLECULAR STRUCTURE; OSTEOBLASTS; OSTEOGENESIS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84883812680     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.07.001     Document Type: Article

References (33)

1. Azzolin L., Zanconato F., Bresolin S., Forcato M., Basso G., Bicciato S., Cordenonsi M., Piccolo S. Role of TAZ as mediator of Wnt signaling. Cell 2012, 151:1443-1456.
2. Bain G., Müller T., Wang X., Papkoff J. Activated β-catenin induces osteoblast differentiation of C3H10T1/2 cells and participates in BMP2 mediated signal transduction. Biochem. Biophys. Res. Commun. 2003, 301:84-91.
3. Chen P., Satterwhite J.H., Licata A.A., Lewiecki E.M., Sipos A.A., Misurski D.M., Wagman R.B. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J. Bone Miner. Res. 2005, 20:962-970.
4. Chen D., Li Y., Zhou Z., Xing Y., Zhong Y., Zou X., Tian W., Zhang C. Synergistic inhibition of Wnt pathway by HIF-1α and osteoblast-specific transcription factor Osterix (Osx) in osteoblasts. PLoS One 2012, 7:e52948.
5. Clement-Lacroix P., Ai M., Morvan F., Roman-Roman S., Vayssiere B., Belleville C., Estrera K., Warman M.L., Baron R., Rawadi G. Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:17406-17411.
6. Clevers H., Nusse R. Wnt/β-catenin signaling and disease. Cell 2012, 149:1192-1205.
7. Eijken M., Meijer I.M., Westbroek I., Koedam M., Chiba H., Uitterlinden A.G., Pols H.A., van Leeuwen J.P. Wnt signalling acts and is regulated in a human osteoblast differentiation dependent manner. J. Cell. Biochem. 2008, 104:568-579.
8. Fukata S., Hagino H., Okano T., Yamane I., Kameyama Y., Teshima R. Effect of intermittent administration of human parathyroid hormone on bone mineral density and arthritis in rats with collagen-induced arthritis. Arthritis Rheum. 2004, 50:4060-4069.
9. Gambardella A., Nagaraju C.K., O'Shea P.J., Mohanty S.T., Kottam L., Pilling J., Sullivan S., Djerbi M., Koopmann W., Croucher P.I., Bellantuono I. Glycogen synthase kinase-3α/β inhibition promotes in vivo amplification of endogenous mesenchymal progenitors with osteogenic and adipogenic potential and their differentiation to the osteogenic lineage. J. Bone Miner. Res. 2011, 26:811-821.
10. Glass D.A., Bialek P., Ahn J.D., Starbuck M., Patel M.S., Clevers H., Taketo M.M., Long F., McMahon A.P., Lang R.A., Karsenty G. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev. Cell 2005, 8:751-764.
11. Hale L.V., Sells Galvin R.J., Risteli J., Harvey A.K., Yang X., Cain R.L., Zeng Q., Frolik C.A., Sato M., Schidt A.L., Geiser A.G. PINP: a serum biomarker of bone formation in the rat. Bone 2007, 40:1103-1109.
12. Halleen J.M., Ylipahkala H., Alatalo S.L., Janckila A.J., Heikkinen J.E., Suominen H., Cheng S., Vaananen H.K. Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density. Calcif. Tissue Int. 2002, 71:20-25.
13. Halleen J.M., Tiitinen S.L., Ylipahkala H., Fagerlund K.M., Vaananen H.K. Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. Clin. Lab. 2006, 52:499-509.
14. Harada H., Nakayama T., Nanaka T., Katsumata T. Effects of bisphosphonates on joint damage and bone loss in rat adjuvant-induced arthritis. Inflamm. Res. 2004, 53:45-52.
15. Hartmann C.A. Wnt canon orchestrating osteoblastogenesis. Trends Cell Biol. 2006, 16:151-158.
16. Hong J.H., Yaffe M.B. TAZ: a beta-catenin-like molecule that regulates mesenchymal stem cell differentiation. Cell Cycle 2006, 5:176-179.
17. Hong J.H., Hwang E.S., McManus M.T., Amsterdam A., Tian Y., Kalmukova R., Mueller E., Benjamin T., Spiegelman B.M., Sharp P.A., Hopkins N., Yaffe M.B. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 2005, 309:1074-1078.
18. Huh J.-E., Ko R., Jung H.J., Lee S.Y. Glycogen synthase kinase 3β promotes osteogenic differentiation of murine adipose-derived stromal cells. PLoS One 2013, 8:e54551.
19. Janckila A.J., Neustadt D.H., Nakasato Y.R., Halleen J.M., Hentunen T., Yam L.T. Serum tartrate-resistant acid phosphatase isoforms in rheumatoid arthritis. Clin. Chim. Acta 2002, 320:49-58.
20. Jang H.D., Shin J.H., Park D.R., Hong J.H., Yoon K., Ko R., Ko C.Y., Kim H.S., Jeong D., Kim N., Lee S.Y. Inactivation of glycogen synthase kinase-3β is required for osteoclast differentiation. Biol. Chem. 2011, 286:39043-39050.
21. Kirstein B., Chambers T.J., Fuller K. Secretion of tartrate-resistant acid phosphatase by osteoclasts correlates with resorptive behavior. J. Cell. Biochem. 2006, 98:1085-1094.
22. Krause U., Harris S., Green A., Ylostalo J., Zeitouni S., Lee N., Gregory C.A. Pharmaceutical modulation of canonical Wnt signalling in multipotent stromal cells for improved osteoinductive therapy. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:4147-4152.
23. Kugimiya F., Kawaguchi H., Ohba S., Kawamura N., Hirata M., Chikuda H., Azuma Y., Woodgett J.R., Nakamura K., Chung U.I. GSK-3beta controls osteogenesis through regulating Runx2 activity. PLoS One 2007, 2:e837.
24. Kulkarni N.H., Onyia J.E., Zeng Q., Tian X., Liu M., Halladay D.L., Frolik C.A., Engler T., Wei T., Kriauciunas A., Martin T.J., Sato M., Bryant H.U., Ma Y.L. Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J. Bone Miner. Res. 2006, 21:910-920.
25. Li B., Shi M., Li J., Zhang H., Chen B., Chen L., Gao W., Giuliani N., Zhao R.C. Elevated tumor necrosis factor-α suppresses TAZ expression and impairs osteogenic potential of Flk-1+ mesenchymal stem cells in patients with multiple myeloma. Stem Cells Dev. 2007, 16:921-930.
26. Marsell R., Sisask G., Nilsson Y., Sundgren-Andersson A.K., Andersson U., Larsson S., Nilsson O., Ljunggren O., Jonsson K.B. GSK-3 inhibition by an orally active small molecule increased bone mass in rats. Bone 2012, 50:619-627.
27. Monroe D.G., McGee-Lawrence M.E., Oursler M.J., Westendorf J.J. Update on Wnt signaling in bone cell biology and bone disease. Gene 2012, 492:1-18.
28. Nakashima K., Zhou X., Kunkel G., Zhang Z., Deng J.M., Behringer R.R., de Crombrugghe B. The novel zinc finger-containing transcription factor Osx is required for osteoblast differentiation and bone formation. Cell 2002, 108:17-29.
29. Reinhold M.I., Naski M.C. Direct interactions of Runx2 and canonical Wnt signaling induce FGF18. J. Biol. Chem. 2007, 282:3653-3663.
30. Theriault R.L. Biology of bone metastases. Cancer Control 2012, 19:92-101.
31. Tuukkanen J., Koivukangas A., Jämsä T., Sundquist K., Mackay C.A., Marks S.C. Mineral density and bone strength are dissociated in long bones of rat osteopetrotic mutations. J. Bone Miner. Res. 2000, 15:1905-1911.
32. Zaragosi L.E., Wdziekonski B., Fontaine C., Villageois P., Peraldi P., Dani C. Effects of GSK3 inhibitors on in vitro expansion and differentiation of human adipose-derived stem cells into adipocytes. BMC Cell Biol. 2008, 9:11.
33. Zhang C., Cho K., Huang Y., Lyons J.P., Zhou X., Sinha K., McCrea P.D., de Crombrugghe B. Inhibition of Wnt signalling by the osteoblast-specific transcription factor Osterix. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:6936-6941.